ARS Pharmaceuticals SPRY
NASDAQ SPRY
$5.62 -0.05 (-0.88%)
As of: Sep 4, 2026 · 3:59 PM EDT

ARS Pharmaceuticals (SPRY) Net Equity Issued and Repurchased (2020 - 2021)

ARS Pharmaceuticals (SPRY) posted Net Equity Issued and Repurchased of $54.8 million for Q4 2021, up 109712.0% sequentially from -$50000.0 in Q4 2020, and up 109712.0% YoY from N/an in Q4 2020.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

ARS Pharmaceuticals (SPRY) Net Equity Issued and Repurchased (2020 - 2021) Analysis & Trends

ARS Pharmaceuticals has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $54.8 million in Q4 2021.

  • Quarterly Net Equity Issued and Repurchased rose 109712.0% year-over-year to $54.8 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $174.4 million (up 13.76% YoY) and the FY2021 annual result came in at $54.8 million, down 64.26% from the prior year.
  • Net Equity Issued and Repurchased advanced to $54.8 million in Q4 2021 per SPRY's latest filing, from -$50000.0 in the prior quarter.
  • Over five years, Net Equity Issued and Repurchased peaked at $119.7 million in Q3 2020 and troughed at -$50000.0 in Q4 2020.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 141.90 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 ARS Pharmaceuticals 561.12 Mn 417.27 Mn 20.81 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 54.81 Mn
Dec 31, 2020 -50,000.00
Sep 30, 2020 119.69 Mn
Jun 30, 2020 12.05 Mn
Mar 31, 2020 21.66 Mn